Evaluation of Polymeric Nanoparticle Formulations by Effective Imaging and Quantitation of Cellular Uptake for Controlled Delivery of Doxorubicin
Source abstract
Abstract
Various polymeric nanoparticles have been extensively engineered for applications in controlled drug release delivery in the last decades. Currently, there is a great demand to develop a strategy to qualitatively and quantitatively evaluate these polymeric nanoparticle formulations for producing innovative delivery systems. In this work, a screening platform is developed using luminescent quantum dots as drug model and imaging label to evaluate nanoparticle formulations incorporating either hydrophilic or hydrophobic drugs and imaging agents. It is validated that there is no influence of the incorporated entities on the cellular uptake profile. The use of quantum dots enables efficient detection and precise quantitation of cellular uptake of particles which occupy 25% of the cell volume. The correlation of quantum dot‐ and doxorubicin‐incorporated nanoparticles is useful to develop an evaluation platform for nanoparticle formulations through imaging and quantitation. This platform is also used to observe the surface properties effect of other polymers such as chitosan and poly(ethylene) glycol on the cellular interaction and uptake. Moreover, quantum dots can be used to study microparticle theranostic delivery formulations by deliberately incorporating as visible ring surrounding the microparticles for their easy identifying and tracing in diagnostic and chemotherapeutic applications.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Quantum Dots Synthesis And Properties · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Materials Research and Engineering A*STAR (Agency for Science Technology, and Research) 3 Research Link Singapore 117602
Department of Biomedical Engineering National University of Singapore Singapore 117575
References (34)
Show source-provided references
1. M.Alazraki The 10 biggest‐selling drugs that are about to lose their patent http://www.dailyfinance.com/2011/02/27/top‐selling‐drugs‐are‐about‐to‐lose‐patent‐protection‐ready accessed: December 2013.
2. T.Staton Top 10 drug patent losses of 2014 http://www.fiercepharma.com/special‐reports/top‐10‐drug‐patent‐losses‐2014 accessed: December 2013.
3. 10.1300/J026v14n03_0810.1300/J026v14n03_08 ↗
4. S.Zhang Eli Lilly sees buyouts as answer to patent expirations http://news.medill.northwestern.edu/chicago/news.aspx?id = 228087 accessed: March 2014.
5. P.Wright Modified release formulations give new life to drugs http://www.pharmaceuticalcommerce.com/index.php?pg = manufacturing_and_packaging&articleid = 27193&keyword = drugs‐pharmacology‐technologies‐FDA accessed: July 2014.
6. 10.1007/s10059-011-0051-510.1007/s10059-011-0051-5 ↗
7. 10.1002/adma.20090393310.1002/adma.200903933 ↗
8. 10.1039/c1jm10712g10.1039/c1jm10712g ↗
9. 10.1158/1078-0432.CCR-07-144110.1158/1078-0432.CCR-07-1441 ↗
10. 10.1039/c2tb00310d10.1039/c2tb00310d ↗
11. 10.1016/j.nano.2013.08.00410.1016/j.nano.2013.08.004 ↗
12. 10.1146/annurev-anchem-060908-15513610.1146/annurev-anchem-060908-155136 ↗
13. 10.1038/nprot.2013.11210.1038/nprot.2013.112 ↗
14. 10.1002/smll.20040013610.1002/smll.200400136 ↗
15. 10.1002/smll.20130043310.1002/smll.201300433 ↗
16. 10.1016/S0168-3659(00)00305-910.1016/S0168-3659(00)00305-9 ↗
17. 10.1016/S0939-6411(00)00062-X10.1016/S0939-6411(00)00062-X ↗
18. 10.1016/S0378-5173(99)00422-610.1016/S0378-5173(99)00422-6 ↗
19. 10.1016/S0168-3659(00)00294-710.1016/S0168-3659(00)00294-7 ↗
20. 10.1007/s11095-008-9763-410.1007/s11095-008-9763-4 ↗
21. 10.1186/1477-3155-10-2010.1186/1477-3155-10-20 ↗
22. 10.1186/1471-2210-5-1110.1186/1471-2210-5-11 ↗
23. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
24. 10.1080/1061186070153958410.1080/10611860701539584 ↗
25. 10.1016/S0169-409X(00)00131-910.1016/S0169-409X(00)00131-9 ↗
26. 10.3109/0898210950901267410.3109/08982109509012674 ↗
27. 10.1016/S0168-3659(99)00248-510.1016/S0168-3659(99)00248-5 ↗
28. 10.1289/ehp.800610.1289/ehp.8006 ↗
29. 10.1021/es052263510.1021/es0522635 ↗
30. 10.1002/smll.20120039810.1002/smll.201200398 ↗
31. 10.1021/jp971091y10.1021/jp971091y ↗
32. 10.1016/S0168-3659(02)00127-X10.1016/S0168-3659(02)00127-X ↗
33. 10.1021/cm034081k10.1021/cm034081k ↗
34. 10.1016/j.biomaterials.2004.07.05010.1016/j.biomaterials.2004.07.050 ↗